Trial · NCT00673387
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Gastrointestinal disorders | Placebo | 4 | 75 | 4 |
| other | nausea | Gastrointestinal disorders | Pramlintide 360 mcg | 31 | 77 | 37 |
| other | nausea | Gastrointestinal disorders | Metreleptin 5.0 mg | 4 | 72 | 4 |
| other | nausea | Gastrointestinal disorders | Pramlintide 180 mcg + Metreleptin 2.5 mg | 27 | 75 | 30 |
| other | nausea | Gastrointestinal disorders | Pramlintide 180 mcg + Metreleptin 5.0 mg | 21 | 78 | 22 |
| other | nausea | Gastrointestinal disorders | Pramlintide 360 mcg + Metreleptin 1.25 mg | 26 | 78 | 27 |
| other | nausea | Gastrointestinal disorders | Pramlintide 360 mcg + Metreleptin 2.5 mg | 29 | 78 | 32 |
| other | nausea | Gastrointestinal disorders | Pramlintide 360 mcg + Metreleptin 5.0 mg | 19 | 75 | 20 |
| other | injection site erythema | General disorders | Placebo | 1 | 75 | 1 |
| other | injection site erythema | General disorders | Pramlintide 360 mcg | 7 | 77 | 8 |
| other | injection site erythema | General disorders | Metreleptin 5.0 mg | 15 | 72 | 25 |
| other | injection site erythema | General disorders | Pramlintide 180 mcg + Metreleptin 2.5 mg | 15 | 75 | 17 |
| other | injection site erythema | General disorders | Pramlintide 180 mcg + Metreleptin 5.0 mg | 17 | 78 | 21 |
| other | injection site erythema | General disorders | Pramlintide 360 mcg + Metreleptin 1.25 mg | 8 | 78 | 9 |
| other | injection site erythema | General disorders | Pramlintide 360 mcg + Metreleptin 2.5 mg | 24 | 78 | 25 |
| other | injection site erythema | General disorders | Pramlintide 360 mcg + Metreleptin 5.0 mg | 21 | 75 | 24 |
| other | injection site pruritus | General disorders | Placebo | 1 | 75 | 1 |
| other | injection site pruritus | General disorders | Pramlintide 360 mcg | 4 | 77 | 4 |
| other | injection site pruritus | General disorders | Metreleptin 5.0 mg | 13 | 72 | 19 |
| other | injection site pruritus | General disorders | Pramlintide 180 mcg + Metreleptin 2.5 mg | 19 | 75 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00673387/events